China’s Brain-Computer Interface Industry Surges Ahead
▼ Summary
– China’s BCI industry is rapidly commercializing with strong policy support, including provincial medical pricing and a national roadmap targeting key milestones by 2027 and 2030.
– A major driver is China’s vast clinical resources and integrated health insurance system, which accelerates trials and commercialization compared to markets like the U.S. and Europe.
– The sector benefits from mature industrial manufacturing for fast R&D and significant strategic investment from both state-led funds and private capital.
– The technology is advancing on two main paths: invasive, implantable BCIs for precision and noninvasive systems for safety and scalability, with new approaches like ultrasound emerging.
– The market is projected to grow significantly, from over $530 million in 2025 to over 120 billion yuan by 2040, with future use expanding from healthcare into human augmentation.
While global attention often focuses on high-profile ventures like Neuralink, China’s brain-computer interface (BCI) sector is rapidly transitioning from academic research to widespread commercialization. A dynamic ecosystem of startups is advancing both implantable and noninvasive technologies, fueled by decisive policy backing, extensive clinical resources, and significant capital investment. Industry pioneer Phoenix Peng, founder of implant maker NeuroXess and noninvasive ultrasound BCI company Gestala, observes that several provinces have already established medical service pricing for BCI procedures, a critical step toward national insurance coverage.
Peng envisions the technology evolving from strictly medical applications into the realm of human enhancement. “Neuroscience and artificial intelligence are two sides of the same coin,” he states. “Their deep integration will create direct, high-bandwidth connections between the human brain and AI. BCI is the ultimate bridge between carbon-based and silicon-based intelligence, which points toward a future market of immense scale.”
Four primary drivers are accelerating China’s BCI progress. First, coordinated policy support provides clear direction. A national roadmap released in August 2025 by multiple government agencies outlines technical goals for 2027 and aims for a complete industrial supply chain by 2030. This is complemented by substantial funding, including a newly announced 11.6 billion yuan ($165 million) brain science fund.
The second factor is China’s vast clinical environment. Large patient populations and integrated national health insurance streamline clinical trials and speed up commercialization post-approval. Researchers have already completed the country’s first fully implanted, wireless BCI trial. “Chinese firms have made clinical strides in motor decoding, spinal cord reconstruction, and stroke rehabilitation,” Peng notes, adding that over 50 flexible implantable BCI trials were completed by mid-2025.
Third, the country’s mature manufacturing base in semiconductors, AI, and medical hardware enables rapid research, development, and prototyping. Finally, strategic investment is pouring in from both state-guided funds and private venture capital. Recent activity includes StairMed Technology’s $48 million Series B round and BrainCo’s reported preparations for a Hong Kong IPO after raising $287 million. Gestala itself is currently negotiating an angel funding round.
Consequently, the Chinese BCI market is projected for substantial growth. Estimates suggest it reached over $530 million in 2025, with forecasts predicting an expansion to over 120 billion yuan by 2040. A competitive field is emerging, with active players like NeuroXess, Neuracle, NeuralMatrix, and BrainCo developing technologies ranging from implantable flexible electrodes to noninvasive headsets.
The industry is broadly divided into two paths. Invasive BCIs, such as those from NeuroXess, implant electrodes directly into the brain for high-precision signal capture but carry surgical risks. Noninvasive systems, like those from BrainCo, prioritize safety and ease of use, though with some trade-off in signal resolution. The landscape is further diversifying with new approaches, including ultrasound, optical methods, and hybrid systems.
Noninvasive technologies are seen as key to overcoming patient adoption barriers, as many individuals are reluctant to undergo brain surgery. Companies like Gestala are targeting widespread conditions such as chronic pain, depression, and stroke rehabilitation. Early clinical results for their ultrasound technology show promise, with a single session reportedly reducing pain scores by fifty percent for one to two weeks.
Investors are scrutinizing the balance between innovation and practical application. HongShan Capital, an investor in implant-focused startup Zhiran Medical, emphasizes the importance of sustainable business models. Partner Yang Yunxia notes that while some technologies seem advanced, they may be far from real-world use, whereas others face hurdles like high costs or technical complexity.
Looking ahead, the next five years will likely see China’s BCI regulatory framework increasingly align with international standards, using guidelines from bodies like the IEC, ISO, and the U.S. FDA as references. Regulators are expected to tighten oversight for invasive devices and data governance while facilitating approvals for noninvasive technologies. Ethical considerations will also come to the fore, with plans to strengthen informed consent protocols, expand ethics reviews, and unify clinical evaluation standards.
(Source: TechCrunch)